SAN DIEGO, Sept. 22, 2025 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from the Phase 2 SAVITRI™ study, which showed statistically significant and clinically meaningful improvement in depression severity at Day 28 and Day 56 with…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
